Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added revision notes for v3.4.3 on 2026-03-05 and 2026-03-06; older revision v3.4.2 is listed under deletions.
    Difference
    0.3%
    Check dated 2026-03-12T02:22:02.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    New update entries were added for 2026-02-20, 2026-02-21, and 2026-02-24. Older update entries for 2026-02-14, 2026-02-17, and 2025-11-28 were removed.
    Difference
    0.3%
    Check dated 2026-02-25T18:54:02.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Adds two new study update dates (2026-02-14 and 2026-02-17) and removes two earlier dates (2026-01-15 and 2026-01-16). No core trial details, including eligibility, interventions, or outcomes, appear to be changed.
    Difference
    0.2%
    Check dated 2026-02-18T16:41:48.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Page now shows Revision: v3.4.2 and the older Revision: v3.4.1 notice has been removed along with a government funding status notice. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T12:08:22.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Added a government funding notice banner about potential delays and that the NIH Clinical Center is open. Updated the page revision to v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T10:38:08.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    Glossary visibility is now shown and two QC-related metadata fields ('Last Update Submitted that Met QC Criteria' and 'Last Update Posted') are displayed, with the page revision updated to v3.4.0. The older entries 'Last Update Submitted that met QC Criteria' and 'Last Update Posted (Estimated)' were removed, along with the lowercase 'No FEAR Act data' in favor of capitalization 'No FEAR Act Data', and the revision was updated from v3.3.4 to v3.4.0.
    Difference
    0.3%
    Check dated 2026-01-28T06:22:40.000Z thumbnail image

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.